I think we made most of our points in our opening remarks or in answering questions.
I would like to ask the committee to focus on the suggestions we have for looking at the patented medicine notice of compliance regulations. They are unique to pharmaceuticals. They block a generic from getting approval at Health Canada until it litigates patents. It encourages, almost demands, litigation. The biggest problem right now is that it doesn't settle the issue and there's ongoing litigation.
We have made proposals to Industry Canada. We would urge the committee to look at that. I think it is generating excessive litigation and business uncertainty. It could be improved and still provide good protection.